Both serum IgA and IgG autoantibodies against TIF1γ present the diagnostic value for the patients with LC at early stage, of which anti-TIF1γ-IgA is demonstrated to be a preferable biomarker, and the combined detection of anti-TIF1γ-IgA and anti-TIF1γ-IgG might contribute to the further improvement of early diagnosis for LC. The gene discussed is TRIM33; the disease is laryngotracheoesophageal cleft.